Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIndivior Regulatory News (INDV)

Share Price Information for Indivior (INDV)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,240.00
Bid: 1,240.00
Ask: 1,245.00
Change: -37.00 (-2.90%)
Spread: 5.00 (0.403%)
Open: 1,277.00
High: 1,284.00
Low: 1,240.00
Prev. Close: 1,277.00
INDV Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Final Court Approval Concludes Antitrust MDL

29 Feb 2024 07:00

RNS Number : 8632E
Indivior PLC
29 February 2024
 

Court Provides Final Approval of Settlement with Direct Purchaser Class in the Multidistrict Antitrust Litigation; Final Court Approval Concludes the Antitrust Multidistrict Litigation

 

Richmond, VA, February 29, 2024 - Indivior PLC (LSE: INDV; Nasdaq: INDV), a leading addiction treatment company, today announced that its subsidiary, Indivior Inc., has received final Court approval for its settlement with the Direct Purchaser class, concluding the anti-trust multi-district litigation ("MDL") matter.

 

On October 22, 2023, Indivior Inc. entered into a settlement agreement with the remaining Direct Purchaser class for $385m. On February 27, 2024, the United States District Court for the Eastern District of Pennsylvania entered an order granting final judgement and order of dismissal approving the Direct Purchaser class settlement and dismissing the Direct Purchaser class claims. This ruling concludes the Antitrust MDL.

 

About Indivior

Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat addiction and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of substance use disorder (SUD). Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder. Headquartered in?the United States?in?Richmond, VA, Indivior employs more than 1,100 individuals globally and its portfolio of products is available in 37 countries worldwide. Visit?www.indivior.com?to learn more. Connect with Indivior on LinkedIn by visiting?www.linkedin.com/company/indivior.

 

Media Contacts:

US Media:

Cassie France-Kelly

Vice President, Communications

Indivior PLC

Tel: 804-724-0327

 

UK Media:

Teneo

Tel: +44 207-353-4200

 

Investors and Analysts

Jason Thompson

Vice President, Investor Relations

Indivior PLC

Tel: 804-402-7123

 

Tim Owens

Director, Investor Relations

Indivior PLC

Tel: 804-263-3978

 

 

-ends-

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBIGDDBXDDGSI
Date   Source Headline
31st Jul 20187:00 amRNSIndivior Preliminary Injunction Upheld
30th Jul 20187:01 amRNSDRL's Appeal of Indivior's PI Granted-in-Part
30th Jul 20187:00 amRNSUS FDA Approves Indivor's PERSERIS(TM)
27th Jul 20188:40 amRNSHolding(s) in Company
26th Jul 20189:01 amRNSHolding(s) in Company
25th Jul 20187:00 amRNSHalf-year Report
24th Jul 20187:00 amRNSHolding(s) in Company
16th Jul 20187:00 amRNSUS Court Grants Indivior Preliminary Injunction
13th Jul 20184:39 pmRNSHolding(s) in Company
12th Jul 20185:16 pmRNSHolding(s) in Company
11th Jul 20187:00 amRNSIndivior Sees FY18 Guidance Below Expectations
10th Jul 20187:00 amRNSNotice of Results
3rd Jul 20187:01 amRNSHolding(s) in Company
3rd Jul 20187:00 amRNSHolding(s) in Company
29th Jun 20187:00 amRNSIndivior's Temporary Restraining Order is Extended
21st Jun 20182:56 pmRNSHolding(s) in Company
20th Jun 20187:00 amRNSHolding(s) in Company
18th Jun 20187:00 amRNSIndivior Is Granted Temporary Restraining Order
15th Jun 20183:56 pmRNSHolding(s) in Company
15th Jun 20181:59 pmRNSIndivior Responds to Generic SUBOXONE ® Approvals
7th Jun 20189:30 amRNSHolding(s) in Company
1st Jun 20187:00 amRNSTotal Voting Rights
31st May 20187:00 amRNSCalifornia Department of Insurance subpoena
25th May 20182:25 pmRNSSUBLOCADE(TM) Submitted in Australia for Approval
24th May 20187:00 amRNSIndivior Participating in Jefferies NYC Conference
16th May 20185:50 pmRNSResult of AGM
14th May 20187:00 amRNSIndivior settlement with Par Pharmaceutical
10th May 201811:40 amRNSBlock listing Interim Review
4th May 20182:13 pmRNSDirector/PDMR Shareholding
2nd May 20187:00 amRNS1st Quarter Results
20th Apr 20187:00 amRNSIndivior's SUBLOCADE NDS Accepted by Health Canada
12th Apr 20183:56 pmRNSHolding(s) in Company
11th Apr 20184:02 pmRNSDirector Declaration
11th Apr 20187:00 amRNSNotice of Results
6th Apr 20189:31 amRNSHolding(s) in Company
5th Apr 20187:00 amRNSIndivior Asserts New SUBOXONE(R) Film Patent
4th Apr 20189:28 amRNSDirector/PDMR Shareholding
3rd Apr 20189:33 amRNSHolding(s) in Company
3rd Apr 20187:00 amRNSTotal Voting Rights
29th Mar 20187:00 amRNSIndivior and C4X Enter Licensing Agreement
27th Mar 20184:13 pmRNSHolding(s) in Company
23rd Mar 20187:00 amRNSIndivior Responds to Court Ruling ANDA litigation
22nd Mar 20181:39 pmRNSAnnual Financial Report
13th Mar 20183:14 pmRNSDirector/PDMR Shareholding
12th Mar 20184:30 pmRNSDirector/PDMR Shareholding
2nd Mar 20182:51 pmRNSHolding(s) in Company
2nd Mar 201810:24 amRNSHolding(s) in Company
1st Mar 20181:00 pmRNSIndivior Announces SUBLOCADET Available in US
1st Mar 20187:00 amRNSTotal Voting Rights
28th Feb 20185:45 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.